KEYNOTE-057: Pembrolizumab Monotherapy for High-risk NMIBC Unresponsive to BCG

By Andrea Necchi, MD - Last Updated: February 18, 2023

Andrea Necchi, MD, Medical Oncologist, San Raffaele Hospital and Scientific Institute, highlights the results from cohort B of the phase 2 KEYNOTE-057 trial and speculates on the applicability of pembrolizumab monotherapy for BCG-unresponsive NMIBC.

Post Tags:ASCO GU 2023-Bladder Cancer
Advertisement
Advertisement